CAR-T Cell Therapy Resource Center
News & Information for Healthcare Professionals
VIDEO: CAR T-Cell Therapy in Head and Neck Cancer
Published on Jul 21, 2017
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for...
New insights into why the immune system fails to see cancer
July 3, 2017 (Medical News Today)
Overall, the immune system does a remarkable job defending the body from disease-causing agents. When it comes to...
Case Report: Adoptive T-Cell Tx Shows Promise in Glioblastoma
December 29, 2016 (HealthDay News)
Tumors regressed after intracranial infusions of T cells engineered to target tumor-associated antigen
Treatment with autologous chimeric antigen receptor (CAR)-engineered...
CAR T-Cell Therapy HCP Guide – Quality and Education: Necessary Steps
The manufacturing process for CAR-T cells is similar, even though the design and structure of the tumor specific scFv (single chain fragment variable) may...
StatPearls Question of the Week – #9
What are present hurdles faced with chimeric antigen receptor-engineered T cells (CAR-T cells) therapy?
A. Antigen loss relapse
B. On target/off tumor toxicity
C. Less efficacy...
CAR T-Cell Therapy HCP Guide – CAR Structure
In the manufacturing facility the CAR structure is synthesized using the patient's own T-cells. The CAR is a fusion protein that contains 3 distinct...
CAR T-Cell Therapy HCP Guide – Patient Delivery: The Preinfusion Conditioning Regime
Before the bioengineered T-cells are reinfused, the patient undergoes a conditioning chemotherapy regimen to reduced the competing T-cell population (lymphodepletion), lower the tumor burden...
CAR T-Cell Therapy HCP Guide – How Are CAR T-Cells Manufactured?
CAR T-cell therapy is not yet approved by the FDA and is considered investigational; a patient must enter a clinical trial to receive it....
CAR T-Cell Therapy HCP Guide – CAR T-Cell Therapy at the FDA
Axicabtagene ciloleucel (KTE-C19) from Kite Pharma was the first CAR T-cell therapy submitted to the FDA for approval in March 2017. For the current...
VIDEO: ZUMA1 trial of CD19 CAR T cells for aggressive NHL
July 6, 2017 (ecancer)
Dr Lin speaks with ecancer at EHA 2017 about clinical and biologic outcomes in patients with refractory aggressive Non-Hodgkin Lymphoma (NHL)...
